U.S. Markets open in 2 hrs 26 mins

Ampio Pharmaceuticals, Inc. (AMPE)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
0.8163+0.02 (+2.05%)
At close: 4:01PM EDT
People also watch
ANTHACRXMRNSALIMAVEO
Interactive chart
Previous Close0.7999
Open0.8001
Bid0.7001 x 100
Ask1.0000 x 5100
Day's Range0.8000 - 0.8300
52 Week Range0.5200 - 4.1900
Volume164,908
Avg. Volume338,283
Market Cap46.73M
Beta0.60
PE Ratio (TTM)-3.14
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals2 months ago

    Colorado biotech's accountants express 'substantial doubt' about firm's future

    In a recent 10-K filing with the Securities and Exchange Commission, Douglas County-based Ampio (AMPE) said "a 'going concern' opinion could impair our ability to finance our operations through the sale of debt or equity securities or through bank financing. Ampio is developing Ampion, an anti-inflammatory drug designed to treat to severe pain associated with osteoarthritis of the knee , which company officials are excited about. In the history of the company, we have never been as close to realizing what we believe to be the full potential of Ampion, both from a regulatory perspective as well as commercial," said Michael Macaluso, chairman, and CEO, in a statement .

  • TheStreet.com10 months ago

    7 Stocks Under $10 That Could Make You a Lot of Money

    When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

  • Answering Two Most Important Questions Surrounding Ampio Pharmaceuticals Inc (AMPE)
    Insider Monkey11 months ago

    Answering Two Most Important Questions Surrounding Ampio Pharmaceuticals Inc (AMPE)

    Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) has recently reported topline from its PIVOT trial and the stock lost over 60% on the announcement last Thursday. From this decline alone, it’s clear that the company didn’t report anything great, but despite missing the primary endpoint in the trial, management is shooting for an approval on the data. What […]